Kyle C. Garrison

OpenAI has successfully completed a major funding round, reaching a valuation of $157 billion. This financial milestone was supported by major contributions from industry leaders including Microsoft, Nvidia and SoftBank. This strategic influx of capital marks a pivotal moment for OpenAI, as it aims to advance research and development in the field of artificial intelligence. The involvement of such high-profile investors underlines the confidence in OpenAI's vision and its potential impact on the technology sector. The funding round not only reflects OpenAI's strong financial health and promising outlook, but also indicates a deeper commitment from some of the tech industry's…

The basketball community is mourning the loss of Dikembe Mutombo, the NBA's celebrated defensive titan, who died at age 58 following a battle with brain cancer. Widely revered not only for his play but also for his humanitarian efforts, Mutombo's death marks a significant loss for the sport and beyond. Dikembe Mutombo, known for his commanding presence and impactful defensive skills, has carved out a legendary career in the NBA, becoming one of the most formidable shot blockers in league history. His distinct finger wag after blocking shots became his signature move, symbolizing his dominance on the court. Off the…

Microsoft is significantly increasing its investments in artificial intelligence, with plans to commit more than $100 billion in data center deals. This strategic move is set to enhance its AI capabilities and infrastructure globally. As part of its ambitious strategy, Microsoft aims to strengthen its data processing facilities, which are essential to support advanced AI technologies. This expansion underscores the company's commitment to leading the artificial intelligence revolution, which is rapidly transforming industries at all levels. The investment will not only increase Microsoft's data management capabilities, but also generate substantial economic activity in the regions hosting these data centers. It…

A pharmaceutical company's attempt to win approval for a new Alzheimer's treatment, simufilam, continues amid a flurry of controversy and regulatory challenges. Recent investigations have cast doubt on the basic studies supporting simufilam. These concerns increased when scientific journals retracted several studies and key figures at Cassava Sciences, the drug's sponsor, resigned. Despite these setbacks, in September the Securities and Exchange Commission (SEC) accused Cassava Sciences of disseminating misleading data about their clinical trials. However, the company settled these charges by paying $40 million, without admitting any guilt. Interestingly, simufilam is still undergoing Phase 3 trials, involving more than 1,900…